Enamine Marks 35 Years as a Global Drug Discovery Partner, Powered by the REAL Chemical Space
核心洞察
Enamine (搜索) has grown over 35 years from a small grant-funded group in Kyiv into a global drug discovery partner with more than 3,000 employees across six countries.
The creation of the Enamine (搜索) REAL approach unlocked a chemical universe of trillions of synthesizable compounds, becoming the engine behind the company's screening collections and integrated platform.
Enamine (搜索) has evolved from a catalog supplier into a fully integrated partner spanning chemistry, biology, and computational science, now ranking among the top 20 contract research organizations worldwide.
Enamine (搜索), a global leader in early drug discovery, is marking 35 years since its founding in 1991, a period that has transformed the company from a small grant-funded group at the Kyiv Institute of Organic Chemistry into a fully integrated partner to pharmaceutical and biotech companies, drug discovery centers, and academic institutions worldwide. Founder and Owner Andrey A. Tolmachev reflected on the milestone, describing a company that now employs more than 3,000 people across six countries and ranks among the top 20 contract research organizations (CROs) in the field.
The company's origins trace back to a pivotal moment in drug discovery. "When we started this journey back in 1991, the world of drug discovery was on the cusp of a revolution," Tolmachev said. "At that time, high-throughput screening was emerging as a powerful new approach, and we saw a clear opportunity to meet the rapidly growing demand for novel compound libraries, because novel and diverse chemistry was the key to success."
The REAL Approach as a Strategic Turning Point
Tolmachev identified the creation of the Enamine (搜索) REAL approach as the single most consequential strategic milestone in the company's history. "The idea that readily accessible molecules could be built through parallel synthesis in just a few steps unlocked a chemical universe that today holds trillions of synthesizable compounds," he explained. "That single innovation became the engine behind everything we built after, like screening collections and building blocks as well as the integrated platform."
The REAL Database and REAL Space have since grown from millions to tens of billions of synthesizable molecules, reflecting the company's evolving strategy as computational tools and artificial intelligence have advanced.
From Catalog Supplier to Integrated Partner
Enamine (搜索)'s evolution has required a fundamental internal shift in mindset and structure. Tolmachev described the company's realization "that everything, starting from chemistry to biology and computational science, can and should work as a single organism under one big roof."
"Our partners do not need to go to two or three different service providers or catalog companies, they need just one point of contact: they need Enamine (搜索)," he said. This vision demanded a move "from 'what compounds can we provide?' to 'what does our partner need to succeed at every stage?'"
The result is a fully integrated platform that connects world-class chemistry, biology, and computational science with access to ultra-large chemical spaces. "We are no longer another catalog company that supplies compounds," Tolmachev stated. "We have become partners in the entire early drug discovery journey, which starts from target identification up to preclinical studies."
Investment in People as the Foundation
Beyond any single strategic decision, Tolmachev emphasized that the company's greatest asset has been its people. "If I had to name one turning point, it is the thorough investment in people and the knowledge we have gained together every single day over 35 years," he said. "Our scientists and all people in Enamine (搜索) are the around that has always been our greatest asset."
Looking ahead, Tolmachev framed the company's trajectory in forward-looking terms. "At 35, Enamine (搜索) is not a company looking back at its legacy. We are a company accelerating into its most ambitious chapter yet, with the same passion for everyday work, the same commitment, and the same belief that innovation in modern science should be accessible to the entire scientific community globally."